CPhI Online

- Market News

KD Pharma expands CDMO capabilities via asset acquisition

30 Mar 2021

The former Rohner's manufacturing assets will enable omega-3 heavyweight to manufacture difficult, multi-step pharmaceutical intermediates and APIs

The KD Pharma Group has further expanded its pharmaceutical contract manufacturing (CDMO) business by acquiring the manufacturing assets of the former Rohner AG.

The KD Pharma Group is one of the largest omega-3 fatty acid producers in the world. Nearly two years ago, the company acquired a manufacturing site in the UK to expand its capacity for manufacturing omega-3-based intermediates used in producing active pharmaceutical ingredients (APIs).

It also has a contract softgel manufacturing site in the US, as well as other omega-3 manufacturing sites in Norway and Germany.

The company has also strengthened its CDMO team by hiring several key personnel from the former Rohner team.

“KD Pharma has all the technology, capacity, and people to become an even larger player in the CDMO market,” said Oscar Groet, CEO of the KD Pharma Group.

“Rohner was known for its unique chemical processes and technological capabilities, enabling it to manufacture difficult, multi-step pharmaceutical intermediates and APIs." Groet continued: “This is a natural fit with our strategy to create health solutions and provide value to customers by utilizing a unique toolbox of technologies.”

Read More

Related Content